Medmax Solutions

Olaparib 150mg is a prescription medicine used to treat adults who have:
advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. Olaparib  is used alone as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that Olaparib  is right for youadvanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of abnormal BRCA gene or a positive laboratory tumor test for genomic instability called HRD. Olaparib  is used in combination with another anti-cancer medicine, bevacizumab, as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that Olaparib  is right for youovarian cancer, fallopian tube cancer, or primary peritoneal cancer, as maintenance treatment, when the cancer has come back. Olaparib  is used after the cancer has responded to treatment with platinum-based chemotherapyadvanced ovarian cancer with a certain type of abnormal inherited BRCA gene, and have received treatment with 3 or more prior types of chemotherapy medicines. Your healthcare provider will perform a test to make sure that Olaparib  is right for youa certain type of abnormal inherited BRCA gene, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive disease, you should have been treated with hormonal therapy. Your healthcare provider will perform a test to make sure that Olaparib  is right for youmetastatic pancreatic cancer with a certain type of abnormal inherited BRCA gene. Olaparib  is used as a maintenance treatment after your cancer has not progressed on at least 16 weeks of treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure Olaparib  is right for youprostate cancer with certain inherited or acquired abnormal genes called homologous recombination repair (HRR genes). Olaparib  is used when the cancer has spread to other parts of the body (metastatic), and no longer responds to a medical or surgical treatment that lowers testosterone, and has progressed after treatment with enzalutamide or abiraterone. Your healthcare provider will perform a test to make sure Olaparib  is right for youIt is not known if Olaparib  is safe and effective in children.

Important Safety Information:
Olaparib  may cause serious side effects, including:Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with Olaparib . MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Olaparib .
Symptoms of low blood cell counts are common during treatment with Olaparib , but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:before treatment with Olaparib every month during treatment with Olaparib 150mgweekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with Olaparib  until your blood cell counts improve.